- Home
- ATHA vs IBIO Comparison
ATHA vs IBIO Comparison
Compare ATHA & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- IBIO
- Stock Information
- Founded
- ATHA 2011
- IBIO 2008
- Country
- ATHA United States
- IBIO United States
- Employees
- ATHA N/A
- IBIO N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- IBIO Health Care
- Exchange
- ATHA Nasdaq
- IBIO Nasdaq
- Market Cap
- ATHA 14.8M
- IBIO 16.4M
- IPO Year
- ATHA 2020
- IBIO N/A
- Fundamental
- Price
- ATHA $4.07
- IBIO $0.86
- Analyst Decision
- ATHA
- IBIO Strong Buy
- Analyst Count
- ATHA 0
- IBIO 2
- Target Price
- ATHA N/A
- IBIO $5.50
- AVG Volume (30 Days)
- ATHA 47.2K
- IBIO 394.8K
- Earning Date
- ATHA 11-06-2025
- IBIO 11-11-2025
- Dividend Yield
- ATHA N/A
- IBIO N/A
- EPS Growth
- ATHA N/A
- IBIO N/A
- EPS
- ATHA N/A
- IBIO N/A
- Revenue
- ATHA N/A
- IBIO $400,000.00
- Revenue This Year
- ATHA N/A
- IBIO N/A
- Revenue Next Year
- ATHA N/A
- IBIO N/A
- P/E Ratio
- ATHA N/A
- IBIO N/A
- Revenue Growth
- ATHA N/A
- IBIO 77.78
- 52 Week Low
- ATHA $2.20
- IBIO $0.56
- 52 Week High
- ATHA $8.26
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- ATHA 74.28
- IBIO 55.86
- Support Level
- ATHA $4.01
- IBIO $0.78
- Resistance Level
- ATHA $4.59
- IBIO $0.86
- Average True Range (ATR)
- ATHA 0.30
- IBIO 0.04
- MACD
- ATHA -0.05
- IBIO -0.00
- Stochastic Oscillator
- ATHA 47.32
- IBIO 66.53
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.